Solution reagent TauroLock™-U25.000

cardiologyMRSA

Our product range includes specialised catheter lock solutions for patients in different contexts. TauroLock™-U25.000 ensures a particularly strong prophylaxis against occlusion, thanks to the active ingredient urokinase. Indication and effect TauroLock™-U25.000 has been approved for instillation in all central-venous access systems. This lock solution reliably prevents the formation of bacterial biofilms within catheters: Patients can avoid infections and maintain a high patency rate. Composition TauroLock™-U25.000 is based on three active ingredients: taurolidine citrate (4 %) urokinase (25,000 units) Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE), while citrate works as an anticoagulant. Urokinase has a thrombolytic effect, breaking up blood clotting in its early stages. Application Before applying TauroLock™-U25.000, you need to dissolve the vial’s content (25,000 IU urokinase) with 5 ml of TauroLock™. In-between treatment sessions, instil the clear, colourless solution into the vascular access device (VAD). Please note that medical staff must respect the filling volume of each catheter or port system. Contraindications TauroLock™-U25.000 is contraindicated for patients who: have a known allergy to taurolidine, citrate, or urokinase are currently taking medication with known adverse interaction to citrate, taurolidine, or urokinase Safety Prior to the next treatment, TauroLock™-U25.000 must be aspirated and discarded in accordance with the applicable guidelines for infectious waste disposal. Package sizes TauroLock™-U25.000 is available in vials of 5 ml (single dose, 5 vials per box).